Nan Fung
Life Sciences

Focused on innovation and growth in Life Sciences


A global Investor in Life Sciences

Our deep resources, commitment, and knowledge within the Nan Fung Life Sciences family of investment companies make us the ideal partners to scientists, entrepreneurs, and corporations around the world. With a diverse set of experiences, skills, and a track record in company formation, venture capital, and scientific innovation, we focus on delivering opportunities to investors who seek to benefit from long-term value.

Nan Fung Life Sciences

Global Life Sciences Investment Platform

Pivotal Life Sciences >

Global Life Sciences Asset Management Platform

Pivotal bioVenture Partners (US)

Global Life Sciences VC Investor
(excluding Asia)

Pivotal bioVenture Partners (China)

Life Sciences VC Investor
Based in China

Public Investment >

Life Sciences Public

NFLS Platform
Companies >

Building Life Sciences Companies

Fund & Co
Investments >

Investing in Life Sciences Funds


We have an important job to do. Find your role.


Top-Notch Karuna Therapeutics Breaks Out To Record High On Schizophrenia Win

Karuna Therapeutics (KRTX) topped expectations Monday in a study of its schizophrenia treatment, and the biotech stock soared to a record high.On the stock market today, biotech stock Karuna catapulted 71.8% to 241.19. The company tested its drug in patients with schizophrenia for five weeks. At the end of the test, patients who received the drug showed a 9.6-point reduction on a scale of symptoms compared to the placebo recipients. The scale measures 30 items related to psychopathic behavior.

FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older

First and only topical PDE4 inhibitor approved for the treatment of plaque psoriasis, including intertriginous psoriasis
Approved for once-daily treatment in mild, moderate, and severe plaque psoriasis with no limitations on duration of use
Established efficacy – provides rapid clearance of plaques and reduction of itch in all affected areas of the body
Safe and very well-tolerated, steroid-free cream with minimal application site reactions
Commercial product expected to be available by mid-August
Management will host conference call on Monday, August 1 at 8:30 a.m. EDT